Hexarelin holds no marketing approval from any major drug regulator, and that single fact drives everything else about its legal position. It is not a scheduled controlled substance in the United States, yet it is banned in competitive sport at all times and cannot be lawfully sold as a medicine or a supplement, which is why the vials that circulate carry a "research use only" sticker. That sticker describes a market workaround, not a legal status.
Hexarelin has never received marketing approval from the FDA, the EMA, or any other major drug regulator for any indication, which makes it an unapproved new drug that is unlawful to sell for human use in most regulated markets even though it is not a federally scheduled controlled substance in the United States.
No major regulator has granted it marketing approval, and the record shows it never reached the point where approval was on the table. Approval requires a sponsor to file a new drug application backed by controlled trials showing safety and efficacy for a defined indication, followed by review of manufacturing quality and labeling; Hexarelin's human data stopped at earlier-phase studies of growth hormone release and possible cardiac uses. That leaves a practical dead end, because compounding and off-label prescribing both start from an approved drug, so neither one opens a lawful route to a compound with no approved reference product.
Hexarelin's human evidence stops at earlier-phase studies, so it has no new drug application, no approved indication, and no lawful pharmacy route in any major regulated market.
The common assumption is that anything raising growth hormone must sit on the schedules alongside anabolic steroids. It does not. The Controlled Substances Act enumerates specific substances and classes, and Congress placed anabolic steroids in Schedule III by statute without sweeping in growth hormone secretagogues, which prompt the pituitary to release the body's own growth hormone rather than acting as a hormone themselves.
| Criteria | Anabolic steroids | GH secretagogues (Hexarelin) |
|---|---|---|
| US federal schedule | Schedule III by statute | Not scheduled |
| Mechanism the law keyed on | Hormone administered directly | Pituitary prompted to release its own GH |
| Enforcement lane | Controlled-substance law | Food and drug law: unapproved new drug, misbranding |
| Routine possession | Scheduling offense | Not a scheduling offense; other exposure can apply |
Hexarelin sits outside the federal controlled-substance schedules in the United States, so enforcement around it runs through food and drug law as an unapproved new drug rather than through the Controlled Substances Act.
Sport is the one arena where the status carries no ambiguity. The World Anti-Doping Agency's 2026 Prohibited List names the compound outright, as "Examorelin (hexarelin)" under S2.2.4, among the prohibited growth hormone releasing peptides; it is not swept in by a catch-all clause that leaves room for argument. The ban runs at all times, so training-phase use carries the same consequence as competition-day use.
The World Anti-Doping Agency's 2026 Prohibited List names Examorelin (hexarelin) explicitly under section S2.2.4, prohibiting it at all times both in and out of competition.
The "research use only" banner is read by many buyers as a legal shield and by regulators as a marketing device. Regulators weigh the totality of how a product is presented and intended, so the surrounding copy, the dosing suggestions, and the actual customer base can establish human use as the real purpose no matter what the sticker says. Labeling that contradicts the evident purpose invites a misbranding exposure on top of the underlying unapproved-drug problem.
The "not for human consumption" label carries no legal weight once intended use points to human dosing, because regulators classify a product by its presentation and evident purpose rather than by its disclaimer.
No major market has approved Hexarelin for a defined medical indication, so the variation between countries is not about approval; it is about how hard each one restricts and enforces. The United States and the European Union both handle it as an unapproved or unauthorized medicinal product, while Australia's Therapeutic Goods Administration has tightened oversight of performance and image-enhancing peptides to the point where supply and importation carry markedly higher stakes. Some countries go further, criminalizing possession or trafficking of doping substances under dedicated statutes, which turns the same vial from a regulatory matter into a criminal one.
| Criteria | United States | European Union | Australia |
|---|---|---|---|
| Approval status | Unapproved new drug | Unauthorized medicinal product | No approval; TGA-regulated |
| Scheduling | Not federally scheduled | Member-state controls layered on top | Many performance peptides prescription-only or controlled |
| Sale for human use | Unlawful | Unlawful | Unlawful, with tighter supply enforcement |
| Personal importation | Customs seizure possible | Rules vary by member state | Narrow allowances, heightened scrutiny |
Hexarelin is unapproved in every major market, so the difference between countries is enforcement intensity rather than legal status, ranging from customs seizure in the United States to prescription-only or controlled classification of performance peptides under Australia's Therapeutic Goods Administration.
The exposure is not spread evenly across the chain. It concentrates at the border and at the point of supply, while quiet personal possession of an unscheduled compound is often not a distinct crime, though that turns entirely on the jurisdiction and cannot be assumed. The step that changes the picture is handing product to someone else.
Legal exposure escalates sharply from possession to supply, since distributing an unapproved new drug can bring both civil penalties and criminal charges for unlawful distribution and misbranding.
Hexarelin's absence from the market is not the story of a rejected drug. It is the story of a candidate that stalled. The compound came out of 1990s peptide research as a synthetic growth hormone releasing peptide, drew real interest for growth hormone deficiency and for cardiac effects, then ran into the finding that undercut its clinical case: the growth hormone response attenuated with repeated dosing as the pituitary desensitized.
Hexarelin stalled in earlier-phase development because its growth hormone response attenuated with repeated dosing and the large confirmatory trials required for approval were never conducted, not because a regulator reviewed and rejected it.
Educational use only. This article describes what the published scientific and clinical literature reports about Hexarelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
